Skin & hair

The Hormonal and Metabolic Levers in HS

Save

Hidradenitis suppurativa has real hormonal and metabolic threads running through it: flares that track the menstrual cycle, a strong overlap with obesity and insulin resistance, and cases where an anti-androgen medication clearly helps. This walks through what spironolactone and metformin are actually doing, how strong the evidence behind each one really is, and where they fit alongside antibiotics and biologics.

Last updated: July 2026History

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Where the hormonal connection actually comes from

Hidradenitis suppurativa is driven by follicular blockage and immune-mediated inflammation, but it also shows real hormonal fingerprints in many people: flares that cluster around the menstrual cycle, a strong association with obesity and metabolic syndrome, and a disease that skews toward women 1. Those patterns are the reason spironolactone and metformin come up in hidradenitis care at all.

Hormonal and metabolic treatment is an added lever for a particular pattern of hidradenitis, not a substitute for the standard antibiotic, antiseptic, and biologic ladder. A person whose flares track their cycle closely, or who has obesity or insulin resistance alongside their hidradenitis, is the more likely candidate for this approach than someone whose disease does not show that pattern. None of it replaces hs flare care during an active flare, which centers on more immediate measures like compresses and antiseptic washing rather than a hormonal medication that takes weeks to have any effect.

Spironolactone: an anti-androgen borrowed from acne treatment

Spironolactone blocks androgen activity, and the strongest trial evidence for that mechanism's effect on inflammatory skin disease comes from acne: a large randomized, placebo-controlled trial in women found that oral spironolactone measurably improved acne severity compared with placebo 2. Dermatologists extend that anti-androgen rationale to hidradenitis off label, on the reasoning that a drug shown to calm one androgen-driven follicular disease plausibly helps another, though a hidradenitis-specific trial of similar size and rigor does not yet exist.

In practice, spironolactone is more often considered for women whose hidradenitis flares track their menstrual cycle, or who have signs of androgen excess such as irregular periods, rather than offered universally. Periodic blood testing to monitor potassium levels is a standard part of taking it, since the drug affects how the kidneys handle potassium.

Metformin: targeting the metabolic side of the disease

Metformin's rationale in hidradenitis comes from the disease's strong overlap with insulin resistance and metabolic syndrome, on the theory that improving insulin sensitivity might calm the inflammatory and hormonal signaling that insulin resistance amplifies. That overlap with metabolic comorbidity is well documented in the broader hidradenitis literature 1, but a large, dedicated randomized trial establishing that metformin itself changes hidradenitis outcomes is thinner than the evidence behind spironolactone or the biologics.

Being offered metformin for hidradenitis is not a sign the disease is unusually severe — it typically reflects a clinician looking at the metabolic side of a person's overall picture, not just the skin. It is generally considered alongside, not instead of, topical and procedural care already in place, and it is sometimes started as part of managing weight or blood sugar for its own sake, with any effect on hidradenitis treated as a secondary benefit rather than the primary goal.

Where oral contraceptives fit in

Combined oral contraceptives are the other hormonal option that comes up, usually for the same subset of people whose hidradenitis appears to track hormonal cycling, extending the same anti-androgen logic that applies to the grown-up acne decision many women already weigh for acne. None of these three hormonal or metabolic options replace the hs treatment ladder guidelines use to structure hidradenitis care by stage 3.

Choosing among spironolactone, metformin, and a combined oral contraceptive — or combining more than one — depends on a person's full picture: menstrual pattern, weight and metabolic labs, contraceptive needs, and what has already been tried. Guidelines emphasize that this staging framework, not any single hormonal option alone, is what determines the overall treatment plan 3.

How this compares to the biologic evidence tier

For comparison, the strongest hidradenitis-specific evidence sits with the biologic tier: a large randomized, placebo-controlled trial found that adalimumab, the first hs biologic, produced significantly more clinical responses than placebo at twelve weeks in moderate-to-severe hidradenitis 4. That is a meaningfully different evidence base than spironolactone or metformin currently have in hidradenitis specifically.

That gap is why a dermatologist may recommend a biologic for someone whose disease is more advanced, even while also trying a hormonal or metabolic add-on; the two approaches are not mutually exclusive. A person with moderate-to-severe, hormonally patterned hidradenitis may reasonably be on both at once, chosen for different features of the same disease. The newer il-17 biologics for hs are a related option in the same evidence tier, generally considered when adalimumab has not been enough on its own.

What monitoring looks like on either medication

Routine monitoring differs between the two drugs and is worth understanding before starting either. Spironolactone's main monitoring concern is potassium, checked periodically by blood test because the drug changes how the kidneys handle it; metformin's is kidney function, checked before starting and periodically after, along with an expectation of temporary gastrointestinal side effects — nausea or loose stools — that often ease after the first few weeks.

Neither monitoring schedule is unique to hidradenitis; it is the same routine bloodwork used whenever either drug is prescribed for any condition, and it is a reasonable question to raise before starting if it has not already come up in the conversation. Anyone who develops muscle weakness, an irregular heartbeat, or persistent palpitations while on spironolactone should have that reported promptly, since it can signal a potassium imbalance that needs a blood test sooner than scheduled.

How this fits into the broader treatment picture

For milder disease, hs oral antibiotics and topical antiseptic care remain the more established starting point, and a hormonal add-on is typically layered onto that foundation rather than used as a stand-alone first treatment. Someone considering surgery for hidradenitis suppurativa for a heavily scarred, chronically involved area is looking at a different tool entirely — one that addresses established tunnels and scarring rather than the hormonal signaling that may have contributed to how the disease got there.

For early, hurley stage 1 disease, topical and antiseptic care alone is often enough on its own, with a hormonal add-on reserved for flares that are frequent or clearly hormonally patterned. A dermatologist who screens for the metabolic and hormonal comorbidities associated with hidradenitis, rather than treating only the visible nodules, is best positioned to say whether spironolactone, metformin, or a combined oral contraceptive genuinely fits a particular case.

Common questions

Not a single hormonal cause, but real hormonal patterns show up in many cases — flares that track the menstrual cycle, a skew toward women, and a strong overlap with obesity and metabolic syndrome. Those patterns are why hormonal and metabolic medications are considered for some people, alongside the antibiotic, antiseptic, and biologic treatments that address the underlying follicular inflammation.

No. Its use in hidradenitis is off label, extrapolated from randomized trial evidence showing it improves acne in women, another androgen-influenced follicular condition. A dedicated large trial establishing its effect in hidradenitis specifically has not been done, so it is generally offered as an add-on rather than a first-line, guideline-endorsed treatment.

Hidradenitis suppurativa overlaps strongly with insulin resistance and metabolic syndrome, and metformin is thought to calm some of the inflammatory signaling that insulin resistance amplifies. The trial evidence specific to hidradenitis is thinner than for spironolactone or the biologics, so it is typically one part of a broader plan rather than a stand-alone treatment.

No. The biologic tier has the strongest hidradenitis-specific trial evidence of any treatment discussed here, and hormonal or metabolic medications are generally an add-on rather than a substitute, especially for moderate-to-severe disease. Someone can reasonably be on both at once, targeting different features of the same condition.

Periodic blood tests check potassium levels, since spironolactone changes how the kidneys handle potassium. Muscle weakness, an irregular heartbeat, or persistent palpitations are signs worth reporting promptly rather than waiting for the next scheduled test, since they can indicate a potassium imbalance.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When hormonal or metabolic treatment for hidradenitis needs a closer look

  • —Muscle weakness, an irregular heartbeat, or persistent palpitations while taking spironolactone
  • —Persistent nausea, vomiting, or unusual muscle pain while taking metformin
  • —A hidradenitis flare with rapidly spreading redness, warmth, or fever, regardless of what medication is being tried
  • —No improvement in flare frequency after several months on a hormonal or metabolic add-on

Muscle weakness or an irregular heartbeat while on spironolactone, or a flare with spreading redness and fever, both warrant prompt medical attention — urgent care or an emergency department — rather than waiting for a routine follow-up.

This article is general education, not a prescription or a treatment plan. Whether spironolactone, metformin, or a combined oral contraceptive fits a particular case of hidradenitis is a decision for a clinician who can review a person's full medical history.

Did this answer your question?

References

  1. 1.Sabat R, Jemec GBE, Matusiak Ł, et al. (2020). Hidradenitis suppurativa. Nature Reviews Disease Primers. doi:10.1038/s41572-020-0149-1 ✓Hidradenitis suppurativa's follicular/immune pathophysiology and comorbidity profile, including hormonal patterns (menstrual-cycle-linked flares, female predominance) and metabolic comorbidities such as obesity and metabolic syndrome.
  2. 2.Santer M, Lawrence M, Renz S, et al. (2023). Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ. PMID 37192767 ✓Randomized placebo-controlled trial (SAFA) showing oral spironolactone improves acne severity in women, the trial basis dermatologists extend off-label to justify spironolactone's anti-androgen rationale in hidradenitis.
  3. 3.Alikhan A, Sayed C, Alavi A, et al. (2019). North American clinical management guidelines for hidradenitis suppurativa: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. Journal of the American Academy of Dermatology. doi:10.1016/j.jaad.2019.02.067Guideline-based disease-staging framework for hidradenitis suppurativa that structures overall treatment planning, into which hormonal and metabolic add-on options are layered rather than used as a stand-alone treatment.
  4. 4.Kimball AB, Okun MM, Williams DA, et al. (2016). Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. New England Journal of Medicine. doi:10.1056/NEJMoa1504370PIONEER I and II phase 3 trials showing adalimumab significantly increases clinical response versus placebo at week 12 in moderate-to-severe hidradenitis, the strongest hidradenitis-specific evidence tier, used here for comparison against the thinner hormonal and metabolic evidence base.

4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library